Compugen (CGEN)
(Delayed Data from NSDQ)
$2.17 USD
-0.02 (-0.91%)
Updated May 31, 2024 04:00 PM ET
After-Market: $2.18 +0.01 (0.46%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth A Momentum F VGM
Brokerage Reports
0 items in cart
Compugen Ltd. [CGEN]
Reports for Purchase
Showing records 41 - 60 ( 60 total )
Company: Compugen Ltd.
Industry: Medical - Biomedical and Genetics
4Q20 - Combination Immunotherapy May Be the Rescue
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Compugen Ltd.
Industry: Medical - Biomedical and Genetics
Company: Compugen Ltd.
Industry: Medical - Biomedical and Genetics
TIGIT Blockade: Effector Functions and Companion Therapy
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: Compugen Ltd.
Industry: Medical - Biomedical and Genetics
Glass Half Full: Our Top Biotech & Healthcare Ideas for 2021
Provider: Roth Capital Partners, Inc.
Analyst: PIROS E
Company: Compugen Ltd.
Industry: Medical - Biomedical and Genetics
Company: Compugen Ltd.
Industry: Medical - Biomedical and Genetics
Company: Compugen Ltd.
Industry: Medical - Biomedical and Genetics
Healthcare -Strategies and Therapeutic Opportunities to Address Checkpoint (IO) Resistance
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Compugen Ltd.
Industry: Medical - Biomedical and Genetics
Notable Events/Catalysts from Our Coverage Universe for the Remainder of 2020
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Compugen Ltd.
Industry: Medical - Biomedical and Genetics
Company: Compugen Ltd.
Industry: Medical - Biomedical and Genetics
2Q20: Inhibiting Three Checkpoints in PD-1 Refractory Cancer Patients
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Compugen Ltd.
Industry: Medical - Biomedical and Genetics
Company: Compugen Ltd.
Industry: Medical - Biomedical and Genetics
1Q20: Driving Three Parallel Clinical Studies in 2020
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Compugen Ltd.
Industry: Medical - Biomedical and Genetics
Company: Compugen Ltd.
Industry: Medical - Biomedical and Genetics
Company: Compugen Ltd.
Industry: Medical - Biomedical and Genetics
Early but Promising. AACR Update of Checkpoint Inhibitor, COM-701
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Compugen Ltd.
Industry: Medical - Biomedical and Genetics
Checkpoint Blockade Against TIGIT-Competitive Landscape. Any Data at ASCO?
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Compugen Ltd.
Industry: Medical - Biomedical and Genetics
Register for Our Webinar: ACSO Abstract Titles Review '-' April 30th at 10am ET
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Compugen Ltd.
Industry: Medical - Biomedical and Genetics
"Consider Reading" Vol. 12: Bayer/CGEN Characterized A Novel Immune Checkpoint
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Compugen Ltd.
Industry: Medical - Biomedical and Genetics
Company: Compugen Ltd.
Industry: Medical - Biomedical and Genetics
We are initiating with a Buy rating and a $28 price target
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T